• Fariba Abbasi Solid Tumour Research Centre, Urmia University of Medical Sciences, Urmia
  • Arefeh Esmaili Department of Pathology, Shahid Abbasi Hospital, Miandoab
  • Zahra Yekta Department of Community Medicine, Urmia University of Medical Sciences, Urmia
  • Abbas Saffarifard Department of Pathology, Imam Khomeini Hospital, Bilesavar


Background: Ovarian cancers are the leading cause of death among gynaecologic neoplasms. The most common form of ovarian tumours is surface epithelial tumours divided as benign, borderline and malignant. Of particular interest are borderline tumours, because the pathologist may rely on some what vague morphologic criteria. The aim of this study was to evaluate the correlation of tumour suppressor protein P53 with macroscopic and microscopic criteria of ovarian surface epithelial tumours and distinction of borderline from malignant tumours. Methods: We studied 109 ovarian neoplasms including 74 benign, 8 borderline and 27 malignant ovarian epithelial tumours during March 2006–March 2011 in Urmia University of Medical Sciences. Immuno-histochemical staining for P53 performed on paraffin blocks and quantified with 12- point weighted score proposed by W.Y chan. Results: Mean P53 weighted scores in benign, borderline and malignant tumours were 0.20±0.63, 0.76±0.89 and 3.79±4.20, respectively. There was significant difference between malignant and borderline tumours(p=0.002) and between malignant and benign ones (p=0.000).None of 11 immuno-reactive benign and 4 borderline tumours showed P53 expression in > 50% of tumour cells, but 11 out of 15 immuno-reactive malignant tumours (73.3%) expressed p53 in >50% of tumour cells. P53 score significantly increases with mitotic count (p=0.000) and solidification of the tumour (p=0.001). There was no significant correlation with size (p=0.277), papillary structures (p=0.062) and grade (p=0.578). Conclusion: According to our results, P53 staining can be used as a helpful method in distinction of borderline from malignant ovarian epithelial tumours, especially in the manner that expression in >50% of cells favouring malignancy.


Leanne LM, Cook LS, Magliocco AM. A review of p53 expression and mutation in human benign, low malignant potential and invasive epithelial ovarian tumours. Cancer 2003;97(2):389–404.

Chen L, Li L, Chen F, He D. Immuonoexpression and prognostic role of p53 in different subtypes of epithelial ovarian carcinoma. J Biomed Res 2012;26(4):274–7.

Shi HR, Zhang RT. Expression and significance of P53, P21 and CDK1 proteins in epithelial ovarian cancer. Ai Zheng 2009;28(8):882–5.

Aune G, Stunes AK, Tingulstad S, Salvesan O, Synersan U, Top SH. The proliferation markers Ki-67/MIB, Phosphohistone H3, and surviving may contribute in the identification of aggressive ovarian carcinomas. Int J Clin Exp Pathol 2011;4(5);444–53.

Kadkhodayan S, Ghaffarzadehgan K. Corralation of p53 protein expression and clinicopathologic features in ovarian epithelial tumours. Iran J Basic Med Sci 2004;7(1):4–7.

Yoshida A, Sarian LO, Anderade LA, Pignataro F, Pinto GA, Derchain SF. Cell proliferation activity unrelated to COX-2 expression in ovarian tumours. Int J Gynecol Cancer 2007;17(3):607–14.

Gursan N, Sipal S, Calik M, Gundogdu C. P53, Bcl-2, Ki-67 Li (Labeling Index) Status in Benign, Proliferative, And Malignant Ovarian Surface Epithelial Neoplasms. Eurasian J Med 2009;41(1):10–4.

Rusai J. Rosai and Ackerman’s surgical pathology. Elsevier Health Science 2011.

Le Page C, Huntsman DG, Provenche DM, Mes-Masson AM. Predictive and Prognostic Protein Biomarkers in Epithelial Ovarian Cancer: Recommendation for Future Studies. Cancers (Basel) 2010;2(2):913–54.

Bai L, Zhu WG. p53: Structure, Function and Therapeutic Applications. J Cancer Mol 2006;2(4):141–53.

Arik D, Kulacoglu S. p53, bcl-2, and nm23 Expressions in Serous Ovarian Tumours. Correlation with the Clinical and Histopathological Parameters. Turk Patoloji Derg 2011;27(1):38–45.

Chan WY, Cheung KK, Schorge JO, Huang LW, Welch WR, Bell DA, et al. Bcl-2 and p53 Protein Expression, Apoptosis, and p53 Mutation in Human Epithelial Ovarian Cancers. Am J Pathol 2000;156(2):409–17.

Ayadi L, Chaabouni S, Khabie A, Amouri H, Makni S, Guermazi M, et al. Correlation between immunohistochemical biomarkers expression and prognosis of ovarian carcinomas in tunisian patients. World J Oncol 2010;1(3):118–28.

Ozer H. Yenicesu G. Arici S. Cetin M. Tuncer E. Cetin. A. Immunohistochemistry with apoptotic-antiapoptotic proteins (p53, p21, bax, bcl-2), c-kit, telomerase, and metallothionein as a diagnostic aid in benign, borderline, and malignant serous and mucinous ovarian tumours. Diagn Pathol 2012;7:124.